Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Ipilimumab + Pembrolizumab |
Indication/Tumor Type | uveal melanoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | uveal melanoma | no benefit | Ipilimumab + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical study, Yervoy (ipilimumab) and Keytruda (pembrolizumab) combination treatment resulted in an objective response rate of 0% (0/9) and a disease control rate of 56% (5/9) in patients with uveal melanoma, with a median overall survival of 18.4 months (PMID: 29988983). | 29988983 |
PubMed Id | Reference Title | Details |
---|---|---|
(29988983) | Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. | Full reference... |